Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Current Liabilities (2019 - 2025)

BridgeBio Pharma's Total Current Liabilities history spans 7 years, with the latest figure at $288.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 86.51% year-over-year to $288.0 million; the TTM value through Dec 2025 reached $288.0 million, up 86.51%, while the annual FY2025 figure was $288.0 million, 86.51% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $288.0 million at BridgeBio Pharma, up from $216.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $288.0 million in Q4 2025 and bottomed at $94.7 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $134.7 million (2021), against an average of $140.1 million.
  • The largest annual shift saw Total Current Liabilities dropped 21.99% in 2023 before it skyrocketed 86.51% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $135.1 million in 2021, then fell by 10.1% to $121.4 million in 2022, then grew by 18.46% to $143.8 million in 2023, then increased by 7.34% to $154.4 million in 2024, then soared by 86.51% to $288.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Total Current Liabilities are $288.0 million (Q4 2025), $216.6 million (Q3 2025), and $175.9 million (Q2 2025).